

Chloropeptins, New Anti-HIV Antibiotics Inhibiting gp120-CD4 Binding from *Streptomyces* sp.

II. Structure Elucidation of Chloropeptin I

KEIICHI MATSUZAKI, TOMOAKI OGINO, TOSHIKI SUNAZUKA and HARUO TANAKA*

School of Pharmaceutical Sciences, Kitasato University,
Minato-Ku, Tokyo 108 Japan

SATOSHI ŌMURA*

Research Center for Biological Function, The Kitasato Institute,
Minato-Ku, Tokyo 108 Japan

(Received for publication October 3, 1996)

The structure of chloropeptin I, a gp120-CD4 binding inhibitor having a potent anti-HIV activity, was elucidated by ^1H and ^{13}C NMR experiments and chemical degradation. It is a peptide antibiotic consisting of six aryl amino acids residues and an α -oxo aryl acid some of which have chlorine atoms.

Chloropeptins I (**1**) and II (**2**) are peptide antibiotics isolated from a culture broth of *Streptomyces* sp. WK-3419 as potent inhibitors against gp120-CD4 binding^{1,2}. They inhibit strongly both the cytopathic effect assayed in HIV-1-infected MT-4 cells and the syncytium formation in co-cultured HIV-1-infected and uninfected MOLT-4 cells². **1** is a new compound although **2** was identified with complestatin³ which has been reported to inhibit the hemolysis of erythrocytes sensitized by the complement system⁴. In this paper, we wish to report the structure of **1**, elucidated *via* combination of NMR analysis and chemical degradation.

Results and Discussion

1 was obtained as a yellow-brown powder: mp $>300^\circ\text{C}$; $[\alpha]_{\text{D}}^{26}$, -18.7° ($c=0.16$, DMSO); UV $\lambda_{\text{max}}^{\text{MeOH}}$ nm (ϵ), 214 (64,600), 239 (sh), 285 (sh), 291 (14,600) and 304 (sh). **1** was positive to EHRLICH's reagent, but negative to ninhydrin and Sakaguchi reagents. The molecular formula was determined to be $\text{C}_{61}\text{H}_{45}\text{N}_7\text{O}_{15}\text{Cl}_6$ by HRFAB-MS (m/z 1325.1093 (M^+), calcd for 1325.1105). The IR spectrum revealed an amide carbonyl absorption at 1640 cm^{-1} . In the ^{13}C and ^1H NMR spectra (Table 1), the signals of six amide carbonyl carbons, five amide protons and one *N*-methyl group were observed. These data indicate the presence of six amide bonds originated from six amino acids. In the ^1H NMR spectrum, six methine proton signals and two methylene proton signals were observed. Additionally, in the aromatic region,

eighteen proton signals and a couple of high-field shifted *m*-coupled signals at δ 5.70 and 5.99 ($J=2.0\text{ Hz}$) were observed. These results suggest that **1** is a peptide antibiotic containing aryl amino acid residues. The signal patterns of the aromatic region show the presence of seven aromatic ring residues as follows. Each three singlet signals at δ 7.28 (2H), δ 7.36 (2H) and δ 7.82 (2H) indicate the presence of 1,3,4,5-tetra-substituted symmetrical benzene rings. A couple of *m*-coupled signals are originated from a 1,3,4,5-tetra-substituted asymmetrical benzene ring. A pair of doublet signals at δ 6.74 (2H, $J=8.5\text{ Hz}$) and δ 7.08 (2H, $J=8.5\text{ Hz}$) and four double-doublet signals at δ 7.19, δ 6.79, δ 7.14 and δ 7.82 (1H, $J=8.0, 2.0\text{ Hz}$, respectively) revealed the presence of two *p*-substituted benzene ring systems. The seventh aromatic ring residue was deduced to be a 7-substituted indole ring system from the following results: **1** was positive to EHRLICH's reagent; the remaining three aryl proton signals at δ 7.22 ($J=8.0\text{ Hz}$), δ 6.90 ($J=8.0\text{ Hz}$) and δ 7.08 ($J=8.0\text{ Hz}$) indicated the presence of 1,2,3-trisubstituted benzene ring; and a singlet signal at δ 7.64 (1H) and a signal of exchangeable proton at δ 10.57 which were assigned at C-2 and NH group, respectively, were observed.

From the COSY, HMQC and HMBC data, the structures of six amino acid residues (A to F) and a 2-oxoaryl acid residue (G) were determined to be as shown in Fig. 1. Chemical shifts of the quaternary carbons, C-3 and 5 of C, E and G residues (δ 122.1, 121.9 and 122.8) indicated that they attached to chlorine

Table 1. ^{13}C and ^1H NMR spectral data of chloropeptin I (1) in $\text{DMSO}-d_6$.

^{13}C	^1H	(Hz)	^{13}C	^1H	(Hz)
A (4-hydroxyphenylglycine)			E (3,5-dichloro-4-hydroxyphenylglycine)		
C=O	171.5	s	C=O	169.0	s
C α	55.9	d	C α	53.5	d
NH			NH		
1	127.8	s	1'	132.2	s
2,6	128.4	d	2',6'	126.7	d
3,5	115.4	d	3',5'	121.9	s
4	157.3	s	4'	148.2	s
B (N-methyltyrosine)			F (tryptophan)		
C=O	168.6	s	C=O	169.3	s
C α	61.5	d	C α	54.9	d
C β	35.1	t	C β	26.7	t
N-CH $_3$	31.2	q	NH		
1'	134.1	s	1'		8.90 1H d 6.0
2'	130.3	d	2'	126.0	d
3'	123.0	d	3'	107.0	s
4'	156.2	s	3'a	129.1	s
5'	121.5	d	4'	116.7	d
6'	131.6	d	5'	118.7	d
			6'	120.8	d
			7'	125.6	s
			7'a	135.6	s
C (3,5-dichloro-4-hydroxyphenylglycine)			G (2-(3,5-dichloro-4-hydroxyphenyl)-2-oxoacetic acid)		
C=O	169.3	s	C=O	164.5	s
C α	51.7	d	C α	185.4	s
NH			1'	127.2	s
1'	131.3	s	2',6'	130.4	d
2',6'	127.2	d	3',5'	122.8	s
3',5'	122.1	s	4'	157.8	s
4'	148.8	s			
D (4-dihydroxyphenylglycine)			phenol		
C=O	168.1	s			9.41 1H s
C α	55.0	d			9.42 1H bs
NH					9.95 1H bs
1'	126.4	s			10.06 1H bs
2'	112.2	d			
3'	150.6	s			
4'	141.8	s			
5'	126.2	s			
6'	125.9	d			

Fig. 1. Partial structures of chloropeptin I (1).




Fig. 2. HMBC correlation and NOEs of chloropeptin I (1).





Fig. 3. The structure of chloropeptin I (1).



atoms.

Based on 2J and 3J long range correlations from HMBC, the amide connectivities of each residues were established as shown in Fig. 2. Biaryl ether bond between C-4 of Tyr (B) and C-3 of 3,4,5-trisubstituted phenylglycine (D) was confirmed by the findings that the chemical shifts of these carbon atoms were down-field shifted at δ 156.2 and δ 150.6, respectively, and that NOEs were observed between 2-H of D and 3-H, 5-H and 6-H of B, respectively (Fig. 2). The second cyclic system was deduced to be the connection between C-5 of D and C-7 of indole residue, because the strong NOEs were observed between 6-H of D and 1-H, 2-H and 6-H of indole residue. Thus, the structure of **1** was elucidated as shown in Fig. 3.

Configurations of amino acid residues were investigated based on chemical degradation. Acid hydrolysis (6N HCl, 120°C, 20 hours) of **1** gave 4-hydroxyphenylglycine (**3**) and 3,5-dichloro-4-hydroxyphenylglycine (**4**). The absolute configuration of **3** was determined to be D, corresponding to Rf value of a standard sample in

chiral TLC. **4** was also determined to be D-configuration from its optical rotation ($[\alpha]_D = -65^\circ$, $c = 0.1$, in H₂O)³.

As described above, the structure of **1** was elucidated on the basis of NMR and chemical degradation method. **1** has six aryl amino acids and an α -keto-aryl acid residues. (D)-4-hydroxyphenylglycine and (D)-3,5-dichloro-4-hydroxyphenylglycine were determined *via* acid hydrolysis, while the configurations of the other three amino acids, *N*-methyltyrosine, 3,4-dihydroxyphenylglycine and tryptophan remain to be clarified. If the residues of 3,5-dichloro-4-hydroxyphenylglycine, 3,5-substituted-4-hydroxyphenylglycine and 2-(3,5-dichloro-4-hydroxyphenyl)-2-oxo-acetic acid would be biosynthesized *via* 4-hydroxyphenylglycine, all of the 3,5-substituted-4-hydroxyphenylglycine residues should have D configuration. Another compound (**2**) isolated from *Streptomyces* sp. WK-3419 was identified with complestatin. The substituted position at Trp of **1** differs from that of **2**. The mechanism of biosynthesis of **1** and **2** in *Streptomyces* sp. WK-3419 is of interest. The configurations of *N*-methyltyrosine, 4-hydroxyphenyl-

glycine and tryptophan residues are going to discuss in a separate paper⁶⁾.

Experimental

1 and **2** were obtained from a culture broth of *Streptomyces* sp. WK-3419 as described previously¹⁾. FAB-MS spectrum was obtained with a JEOL model JMS-AX505 HA spectrometer. ¹H NMR (400 MHz) and ¹³C NMR (100 MHz) spectra were obtained on a Varian XL-400 spectrometer. Optical rotation was measured with a Jasco DIP-370 polarimeter.

Acid Hydrolysis of **1**

A solution of **1** (65 mg) in 6 N HCl (3 ml) was heated at 120°C for 20 hours in a vacuumed sealed tube, and then concentrated to dryness. The residue was dissolved in water and then purified by HPLC (Shiseido Capcell Pak C18 SG, 20 mm i.d. × 250 mm, mobile phase; 0.05% trifluoroacetic acid) to give **3** (1.5 mg, HRFAB-MS: *m/z* 168.0669 (M+H)⁺, calcd. 168.0661 for C₈H₁₀O₃N) and **4** (4.0 mg, HRFAB-MS: *m/z* 235.9882 (M+H)⁺, calcd. 235.9881 for C₈H₈O₃NCl₂). **3** was identified as D-4-hydroxyphenylglycine by comparison with authentic samples of D and L isomers: R_f values of D- and L- isomers of 4-hydroxyphenylglycine in chiral TLC [Chiral HPTLC plate; CHIR, Merck Art. 14101, mobile phase; acetonitrile-methanol-water (4:1:1)] were 0.63 and 0.75, respectively.

Acknowledgments

We thank Dr. S. TAKAHASHI (Sankyo Co., Ltd.) for providing complestatin. We express our thanks to Ms. A. HATANO and Ms. N. SATO of our university for measuring NMR spectra.

This study was supported by a Grant-in-Aid from the Ministry of Education, Science, Sports and Culture of Japan.

References

- 1) MATSUZAKI, K.; H. IKEDA, T. OGINO, A. MATSUMOTO, H. B. WOODRUFF, H. TANAKA & S. ŌMURA: Chlorozeptins I and II, novel inhibitors against gp120-CD4 binding from *Streptomyces* sp. J. Antibiotics 46: 1173~1174, 1994
- 2) TANAKA, H.; K. MATSUZAKI, H. NAKASHIMA, T. OGINO, A. MATSUMOTO, H. IKEDA, H. B. WOODRUFF & S. ŌMURA: Chlorozeptins, new anti-HIV antibiotics inhibiting gp120-CD4 binding from *Streptomyces* sp. I. Taxonomy, fermentation, isolation, and physico-chemical properties and biological activities. J. Antibiotics 50: 58~65, 1997
- 3) SETO, H.; T. FUJIOKA, K. FURIHATA, I. KANEKO & S. TAKAHASHI: Structure of complestatin, a very strong inhibitor of protease activity of complement the human complement system. Tetrahedron Lett. 30: 4987~4990, 1989
- 4) KANEKO, I.; K. KAMOSHIDA & S. TAKAHASHI: Complestatin, a potent anti-complement substance produced by *Streptomyces lavendulae*. I. Fermentation, isolation and biological characterization. J. Antibiotics 42: 236~241, 1989
- 5) MOMOTA, K.; I. KANEKO, S. KIMURA, K. MITAMURA & K. SHIMADA: Inhibition of human immunodeficiency virus type-1-induced syncytium formation and cytopathicity by complestatin. Biochem. Biophys. Res. Comm. 179: 243~250, 1991
- 6) GOUDA, H.; K. MATSUZAKI, H. TANAKA, S. HIRONO, S. ŌMURA, J. A. MACAULEY, P. A. SPRENGELER, G. T. FURST & A. B. SMITH, III: Stereostructure of (-)-chlorozeptin I, a novel inhibitor of gp120-CD4 binding, via high-temperature molecular dynamics, Monte Carlo conformational searching, and NMR spectroscopy. J. Am. Chem. Soc. 118: 13087~13088, 1996